A new modeling study has found that HPV vaccination could substantially reduce cervical cancer in Tunisia, where it is not yet part of the national immunization program. Using UNIVAC and PRIME models, four vaccines for 12-year-old girls starting in 2025 were assessed for potential impact. All vaccines were cost-effective, with Cecolin emerging as the most cost-effective option overall, while Cervarix offered slightly greater health benefits at high coverage. These findings support introducing HPV vaccination in Tunisia to lessen the cervical cancer burden and optimize health spending.
How can the findings be used?
The four HPV vaccines (Cecolin, Cervarix, Gardasil-4, and Gardasil-9) are cost-effective for Tunisia. These findings provide valuable evidence to guide the country’s decision on introducing HPV vaccination.
Thumbnail image credit: Study authors
Any organization or individual working in the field of immunization economics can submit findings, opportunities, calls to action, or other relevant work below to be shared with our community.